BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Given Consensus Rating of “Hold” by Analysts

Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) have earned a consensus rating of “Hold” from the four ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $11.50.

BTAI has been the topic of a number of analyst reports. HC Wainwright cut their price objective on shares of BioXcel Therapeutics from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Thursday, March 5th. Rodman & Renshaw began coverage on shares of BioXcel Therapeutics in a research report on Tuesday, March 17th. They set a “buy” rating and a $17.00 target price for the company. Zacks Research raised shares of BioXcel Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, March 9th. Wall Street Zen raised BioXcel Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioXcel Therapeutics in a report on Wednesday, January 21st.

BioXcel Therapeutics Price Performance

Shares of BTAI stock opened at $1.21 on Tuesday. The stock’s 50-day moving average is $1.59 and its 200 day moving average is $1.95. BioXcel Therapeutics has a 1-year low of $1.15 and a 1-year high of $8.08. The company has a market cap of $26.46 million, a P/E ratio of -0.18 and a beta of 0.18.

BioXcel Therapeutics (NASDAQ:BTAI) last announced its earnings results on Friday, March 27th. The company reported ($0.58) EPS for the quarter, hitting analysts’ consensus estimates of ($0.58). The firm had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.15 million. On average, analysts anticipate that BioXcel Therapeutics will post -24.39 EPS for the current year.

Institutional Investors Weigh In On BioXcel Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BTAI. Diversify Wealth Management LLC acquired a new stake in BioXcel Therapeutics in the second quarter worth about $27,000. HRT Financial LP acquired a new position in shares of BioXcel Therapeutics during the fourth quarter valued at about $28,000. XTX Topco Ltd acquired a new position in shares of BioXcel Therapeutics during the second quarter valued at about $42,000. Goldman Sachs Group Inc. purchased a new position in shares of BioXcel Therapeutics in the 1st quarter valued at approximately $50,000. Finally, Geode Capital Management LLC boosted its stake in BioXcel Therapeutics by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 28,182 shares of the company’s stock worth $51,000 after purchasing an additional 6,120 shares in the last quarter. 30.68% of the stock is currently owned by hedge funds and other institutional investors.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.